

As part of this study, I am receiving treatment with:

- ☐ JNJ-79635322 (BCMA x GPRC5D x CD3 Tri Specific Antibody for Multiple Myeloma)
- ☐ Teclistamab (TECVAYLI)

If presenting for emergency treatment, please consider evaluation for possible Cytokine Release Syndrome (CRS) and/or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) as part of initial patient evaluation.

Considering the potential seriousness of CRS/ICANS, every effort should be made to perform an immediate medical evaluation of the patient upon arrival at your medical facility. For more information, please contact the treating physician or the study sponsor at the numbers listed on the card.

Back Translated from Hindi to English on 03 Mar 2026

Johnson & Johnson

CARD FOR CLINICAL STUDY PARTICIPANT

*Global Version 1.0 09/Jan/2026
Country Version 1.0 18/Feb/2026*

PARTICIPANT CARD

Always show the card whenever you visit your physician or hospital or are in an EMERGENCY.

Participant Name.....

Doctor in charge.....

Study Number **79635322MMY3002**

Hospital.....

Department.....

Site Number

Participant Number

24-hour emergency contact

This is a clinical study participant. If you are a healthcare professional and need information about the study or the study drug, please contact the investigator.

Local sponsor ☎: 000 80005 01161

Please call the local sponsor only when you are not able to contact the investigator and are in an emergency. Please do not provide your personal data, only the subject number.

Back Translated from Hindi to English on 03 Mar 2026